NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma, a Nasdaq-listed biopharmaceutical company, announced European Commission approval for its novel oral CETP inhibitor obicetrapib, marketed as Ubeslo® (monotherapy) and Evlarco® (in combination with ezetimibe). This first global approval is based on strong clinical trial results demonstrating significant LDL cholesterol reduction…